Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.72 CHF | +1.31% | +3.16% | +15.44% |
May. 03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.44% | 536M | |
+22.81% | 46.81B | |
+46.85% | 41.29B | |
-1.88% | 41.37B | |
-6.20% | 28.87B | |
+11.33% | 26.06B | |
-21.00% | 19.13B | |
-1.43% | 11.96B | |
+30.73% | 12.39B | |
-0.48% | 12.08B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica : Japanese Partner Enrolls Patients for Phase 3 Study of Invasive Aspergillosis Drug Isavuconazole